Home > Insider Trading > Filing (0001062993-25-002225)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1177648	Enanta Pharmaceuticals Inc	ENTA	Pharmaceutical Preparations (2834)	043205099

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1571211	R. Jay Luly	C/O Enanta Pharmaceuticals, Inc. 4 Kingsbury Avenue Watertown MA 02472	President And Ceo	Yes	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2025-02-12	45,000	$5.69	846,638	No	4	P	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Direct

Footnotes

The reporting person's purchase of common stock reported herein was matchable under Section 16(b) of the Securities Exchange Act of 1934, to the extent of 5,142 shares, all of which related to a "sell to cover" transaction required to satisfy tax withholding obligations due as a result of settlement of a portion of a restricted stock unit award granted on November 23, 2022. The reporting person has paid to Enanta $13,861.92, representing the full amount of the profit realized in connection with the short-swing transaction.
The price reported in Column 4 is a weighted-average price. These shares were purchased in multiple transactions at prices ranging from $5.32 to $5.86, inclusive. The reporting person undertakes to provide to Enanta Pharmaceuticals, Inc., any security holder of Enanta Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote of this Form 4.